Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. by Guitart, Joan et al.
UCSF
UC San Francisco Previously Published Works
Title
Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a 
provisional entity in the 2016 WHO classification of cutaneous lymphomas.
Permalink
https://escholarship.org/uc/item/63f8f552
Journal
Modern pathology : an official journal of the United States and Canadian Academy of 
Pathology, Inc, 30(5)
ISSN
0893-3952
Authors
Guitart, Joan
Martinez-Escala, M Estela
Subtil, Antonio
et al.
Publication Date
2017-05-01
DOI
10.1038/modpathol.2016.240
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Primary Cutaneous Aggressive Epidermotropic Cytotoxic T-cell 
Lymphomas: reappraisal of a provisional entity in the 2016 WHO 
classification of cutaneous lymphomas
Joan Guitart, M.D.(1), M. Estela Martinez-Escala, M.D.(1), Antonio Subtil, M.D.(2), Madeleine 
Duvic, M.D.(3), Melissa P. Pulitzer, M.D.(4), Elise A. Olsen, M.D.(5), Ellen Kim, M.D.(6), Alain H 
Rook, M.D.(6), Sara S. Samimi, M.D.(6), Gary S. Wood, M.D.(7), Michael Girardi, M.D.(2), 
Jacqueline Junkins-Hopkins, M.D.(8), Doina S. Ivan, M.D.(3), M. Angelica Selim, M.D.(5), 
Kimberly A. Sable, B.A.(1), Pooja Virmani, M.D.(5), Laura B. Pincus, M.D.(9), Michael T. 
Tetzlaff, M.D.(3), Jinah Kim, MD(10), and Youn H. Kim, M.D.(10)
(1)Departments of Dermatology and Pathology. Northwestern University Feinberg Medical School 
Chicago IL
(2)Departments of Dermatology and Pathology, Yale University, New Haven CT
(3)Departments of Dermatology and Pathology, MD Anderson Houston TX
(4)Departments of Dermatology and Pathology, Sloan Kettering Cancer Center, New York, NY
(5)Departments of Dermatology and Pathology, Duke University, Durham NC
(6)Departments of Dermatology and Pathology, University of Pennsylvania, Philadelphia PA
(7)Departments of Dermatology and Pathology, University of Wisconsin VAMC, Madison WI
(8)Departments of Dermatology and Pathology, Ackerman Academy New York, NY
(9)Departments of Dermatology and Pathology, University of California in San Francisco, San 
Francisco, CA
(10)Departments of Dermatology and Pathology, Stanford University, Stanford, CA
Abstract
Primary cutaneous CD8+ positive aggressive epidermotropic T- cell lymphoma is a rare and 
poorly characterized variant of cutaneous lymphoma still considered a provisional entity in the 
latest 2016 World Health Organization Classification of Cutaneous lymphomas. We sought to 
better characterize and provide diagnostic and therapeutic guidance of this rare cutaneous 
lymphoma. Thirty-four patients with a median age of 77 years (range 19 – 89 years) presented 
primarily with extensive annular necrotic plaques or tumor lesions with frequent mucous 
membrane involvement. The 5-year survival was 32% with a median survival of 12 months. A 
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subset of 17 patients had a prodrome of chronic patches prior to the development of aggressive 
ulcerative lesions. We identified cases with lack of CD8 or αβ T-cell receptor expression yet with 
similar clinical and pathological presentation. Allogeneic stem cell transplantation provided partial 
or complete remissions in 5/6 patients. We recommend the term primary cutaneous aggressive 
epidermotropic cytotoxic T-cell lymphoma as this more broad designation better describes this 
clinical-pathologic presentation which allows the inclusion of cases with CD8 negative and/or αβ/
γδ T-cell receptor chain double positive or double negative expression. We have identified early 
skin signs of chronic patch/plaque lesions that are often misdiagnosed as eczema, psoriasis, or MF. 
Our experience confirms the poor prognosis of this entity and highlights the inefficacy of our 
standard therapies with the exception of allogeneic stem cell transplantation in selected cases.
INTRODUCTION
Primary cutaneous CD8 positive aggressive epidermotropic T-cell lymphoma remains a 
provisional entity in the latest World Health Organization 2016 classification of cutaneous 
lymphomas (1). In part the problem with CD8 positive aggressive epidermotropic T-cell 
lymphoma is that they have been poorly characterized to date due to the rarity of the 
condition. Historically, this condition was known in the dermatology literature as 
generalized pagetoid reticulosis or Ketron-Goodman disease and was characterized by 
rapidly evolving and extensively ulcerated annular plaques associated with a poor prognosis. 
The histopathology has been reported to be characteristic, with an infiltrate of 
monomorphous medium sized atypical lymphocytes involving the epidermal thickness in a 
so-called pagetoid pattern. While clinically this condition was known to result in widespread 
ulcerations from epidermal necrosis, the cytotoxic phenotype with CD8 expression was first 
reported by Agnarsson et al in 1990, and the term CD8 positive aggressive epidermotropic 
T-cell lymphoma was first coined by Berti et al in 1999 (2, 3). We have observed cases with 
similar clinical-pathologic features, cytotoxicity and aggressive course without CD8 
expression. Our goal is to redefine this entity using the more broad and inclusive term 
primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma (PCAECyTCL). 
Herein we present the largest series of primary cutaneous aggressive epidermotropic 
cytotoxic T-cell lymphoma reported to date, collected from several cutaneous lymphoma 
centers in the United States.
MATERIALS AND METHODS
A group of pathologists and dermatologists from some of the largest cutaneous lymphoma 
centers in the United States met on two occasions in Chicago to review each institutional 
experience including the clinical and pathological material of primary cutaneous aggressive 
epidermotropic cytotoxic T-cell lymphoma. Approval from the Institutional Review Board at 
Northwestern University encompassing all centers was obtained. Entering criteria included a 
clinical presentation with patches, plaques or nodules with erosive or necrotic features 
covering more than 1% of the body surface area. Cases with localized pagetoid reticulosis 
(Woringer-Kolopp disease) were excluded. The cases included were characterized by 1) a 
pagetoid pattern of T-cells with expression of at least one pan-T-cell marker 2) positivity for 
CD8 and BF1 (αβ T-cell receptor heterodimer) and 3) negativity for the γδ T-cell receptor 
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heterodimer marker (clone γ3.20, Thermo/Fisher Scientific, Waltham, MA). However, these 
criteria were revised when we encountered cases that fulfilled clinicopathologic criteria but 
with variable CD8 and/or T-cell receptor immunophenotype. An extensive 
immunohistochemistry panel of monoclonal antibodies against CD2, CD3, CD4, CD5, CD7, 
CD8, CD20, CD30, CD45RA, CD56, T-cell intracellular antigen-1 and granzyme B was 
performed in most cases. In addition Epstein-Barr virus ribonucleic acid expression was 
evaluated using Epstein-Barr encoding region in situ hybridization and T-cell receptor 
clonality analysis with polymerase chain reaction based methods using BIOMED-2 protocol 
was reported when available from skin, blood, nodal and bone marrow biopsy samples.
Electronic medical records were reviewed and clinical, imaging and laboratory parameters 
along with clinical photographs when available were presented to the group. Clinical data 
including gender, age, race, nature, extent and duration of the lesions, constitutional 
symptoms, past medical history, results of staging bone marrow biopsy and imaging tests, 
response to therapies, outcome and duration of follow up were obtained. The original 
histopathological slides including immunohistochemical markers were reviewed by the 
group and a consensus diagnosis was rendered. Skin biopsies from the 30 selected patients 
were reviewed. Several parameters, including the distribution of the infiltrate within the 
epidermal, dermal and subcutaneous compartments, distribution of the intraepidermal 
lymphocytes, cell size, adnexotropic features (folliculotropism and syringotropism), 
presence or absence of epidermal necrosis, interface reaction, ulceration, hemorrhage, 
angiocentricity or vasculitis were assessed by the group on a multiheaded microscope. Other 
notable histological findings such as presence of other inflammatory cells (eosinophils, 
neutrophils, plasma cells, histiocytes), granuloma formation, mucin deposits, karyorrhexis or 
hemophagocytosis were documented.
Descriptive statistics including median (with range) and counts (with percentages) were 
determined and compared using U Mann Whitney and Fisher’s Exact tests, respectively. 
Five-year survival rate was performed using Kaplan-Meier method. Categorical clinical and 
pathological characteristics were compared using log-rank tests to overall outcome and 
survival rates. Survival analysis was performed from date of diagnosis. As this was a 
retrospective analysis, data were missing for some cases. All analyses were done on the 
available data. All tests were performed using SPSS statistics software (Chicago, IL) with a 
type I error rate of 5%. P-values less than 0.05 were considered indicative of a trend.
RESULTS
Clinical Data
Upon a consensus review of a total of 52 cases, 30 were deemed to fulfill the diagnostic 
criteria and confirmed by the group as primary cutaneous aggressive epidermotropic 
cytotoxic T-cell lymphoma and 4 additional cases were added to the series over the ensuing 
months (Table 1). One case had been previously published as a case report (4). All cases 
were collected between 1995 and 2015. Most of the cases excluded were redefined after 
reviewing clinical and histological parameters by the group as CD8+ mycosis fungoides, 
pagetoid reticulosis or dermal CD8+ T cell lymphomas without marked epidermotropism or 
pagetoid features.
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The cohort consisted of 34 patients (25 male, 9 female) with a median age of 77 years (range 
19–89 years) including 19 White, 5 Blacks, 4 Hispanic, 1 Asian and 5 of unknown race. The 
median duration of the lesions at the time of presentation was 10 months, ranging from 1 to 
120. In 14 of 31 subjects the onset of symptoms was considered acute appearing within 6 
months from the time of presentation. Seventeen patients had a chronic course longer than 6 
months with poorly characterized preceding skin lesions. There was no survival difference 
from the time of diagnosis between those with an acute versus chronic course (p=.09). The 
skin lesions at presentation were reported as patches or plaques in 24 patients, tumors in 2 
patients (Figure 1a, Case 24) and a combination of both in 7 patients. Ulceration was noted 
at presentation in 10 cases and 20 additional cases evolved into ulcerated plaques overtime. 
Thirteen patients carried an initial diagnosis of “mycosis fungoides”, whereas many other 
cases were initially diagnosed with a benign condition including an eczematous process, 
contact dermatitis, viral or drug eruption, psoriasis (11 cases), lupus erythematosus (2 
cases), erythema multiforme or ulcer. Two patients presented with acute coalescing necrotic 
macules resembling extensive pityriasis lichenoides acuta (Mucha-Habermann disease) 
(Figure 1b, Case 27). We also reviewed skin biopsies from two patients with the preceding 
non-specific skin presentations. In both cases rare scattered intraepidermal atypical 
lymphocytes were noted accompanied with acanthosis, hyperkeratosis and rare necrotic 
keratinocytes. Using the TNM classification system for primary cutaneous lymphomas other 
than mycosis fungoides and Sézary syndrome, multifocal or generalized skin involvement at 
presentation (T3) was reported in 24 patients (5). Two patients presented with a solitary 
lesion (T1) and 4 patients with localized involvement in one anatomic region (T2). Disease 
progression requiring systemic therapy was reported in all patients except in one with 
limited disease. The skin lesions were for the most part annular and erythematous with 
peripheral erosions and ulceration often surmounted with a hemorrhagic-necrotic crust 
(Figure 2a–c, Case 25). The ulcerated patches tended to become more generalized and 
extensive in advanced stages (Figure 2d,e, Case 26). The distribution of the lesions was 
variable with involvement of the upper and/or lower extremities in 29 patients, torso in 23 
and head/neck in 15 patients. Five patients developed ulcers involving the oral cavity and 6 
patients involving genital or perigenital skin (Figure 1c, Case 23 and 2a, Case 25). 
Constitutional symptoms were overall mild with a few patients reporting weight loss (6), low 
grade fever (3) and asthenia (3). Past medical history was significant for 3 patients with solid 
organ cancer (uterine, prostate, melanoma). One of these patients also had Parkinson 
disease, and one patient had a remote history of Hodgkin lymphoma in remission. Only one 
patient was immunosuppressed post-lung transplant and one patient had an unconfirmed 
diagnosis of bullous pemphigoid. Serum lactate dehydrogenase levels were increased at the 
time of presentation (>200 U/L) in 26% (5/19) of the patients. Four patients had abnormal 
peripheral blood results by flow cytometry including one patient with CD8+/CD26+ 
leukemia of 75,000 cells/ml. The same patient was the only one (1/11) with positive bone 
marrow biopsy. Small palpable lymphadenopathy was noted in 6 cases, but none of them 
were considered clinically significant for nodal biopsy. Clinical or pathological signs of 
hemophagocytosis or hepatosplenomegaly were not reported in any of the cases.
Results from imaging studies at presentation were available for 25 patients and were 
reported positive in 11 patients, most commonly demonstrating positron emission 
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tomography avid cutaneous or subcutaneous uptake with only 1 patient with nodal 
involvement and 1 patient with right adrenal involvement.
Follow up information was available for 31 patients with a median follow up time of 12 
months (range 1 – 168 months). Seventeen patients (54%) died during the follow up period 
related to disease progression. Four patients developed extracutaneous disease involving 
lungs (2) and adrenal glands (2). None of the patients developed hemophagocytic syndrome. 
At the last follow up, 12 patients were known to be alive with disease, three alive without 
disease. The 5-year overall survival rate was 32% with a median overall survival of 12 
months.
A median of 3 therapies (range 1–13), including skin-directed and systemic regimens, were 
administered to the cohort. Eight of the 20 patients treated with various chemotherapies were 
alive at the end of the study. Ten patients received localized radiation therapy and 8 patients 
total skin electronbeam therapy. Six patients were treated with allogeneic hematopoietic 
stem cell transplantation and 5 of them were alive at the end of the study including 2 in 
complete remission and 3 with recurrent disease albeit mostly limited to a few sporadic 
lesions. One patient developed extensive extracutaneous disease shortly after allogeneic 
hematopoietic stem cell transplantation while on immunosuppressive medication (detailed 
summary of therapies is presented in Table 2).
Pathology data
Thirty-four biopsies were assessed—The pattern of the lymphoid infiltrate was 
pagetoid in all cases with scattered atypical lymphocytes involving the entire epidermal 
thickness in 20 biopsies, while in 14 biopsies the atypical lymphocytes were predominantly 
confined to the lower half of the epidermis (Figure 3a–d Case 25, Case 34 and Case 29). The 
latter pattern was commonly associated with an atrophic epidermis. Infiltration of cutaneous 
adnexa by the lymphoma cells was common, but eccrine glands or follicular units were 
absent from some skin biopsies (Figure 3e-f, Case 26). Syringotropism of the eccrine glands 
without hyperplastic changes was noted in 18/30 biopsies and folliculotropism in 18/22. 
However, follicular mucinosis or destruction of the follicular unit by the tumor cells as 
commonly seen in folliculotropic MF were not observed in any case. In addition to the 
intraepithelial infiltrate, 9 biopsies had a tumoral dermal component and in 6 additional 
biopsies the infiltrate extended beyond the reticular dermis into the subcutaneous tissue 
(Figure 3e). Focal (12/31) or extensive and confluent (8/31) keratinocyte necrosis was noted 
in 64% of the biopsies with frank ulceration in 7 biopsies. However other biopsies (14/34) 
showed no signs of epidermal necrosis regardless of lymphoid density. Hence necrosis, 
hemorrhage or other histological signs of cytotoxicity may not be observed in some skin 
biopsies of early evolving lesions. Intraepidermal aggregates of atypical lymphocytes 
resembling Pautrier’s microabscesses were observed in 16/34, more commonly seen in 
biopsies with high intraepidermal lymphoid density, rather than the scattered 
microaggregates usually seen in MF. Mild acanthosis was noted in 15 biopsies, but none of 
the samples had the verrucous hyperplasia so characteristic of pagetoid reticulosis. While 
upper dermal extravasation of erythrocytes was common (20/34) often with subtle 
infiltration of small vessel walls (3/34), fibrinoid vascular necrosis was not noted. However, 
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frank angiocentric or angiodestructive features were not identified in any of the cases. 
Likewise, modest and focal neurotropism was observed in 5/34 cases. Only one of these 
biopsies was associated with CD56 (neural cell adhesion molecule) expression and none of 
them had clinical signs of neuropathy. A minor component of eosinophils in the infiltrate 
was observed in (13/34) including 9 with folliculotropism/syringotropism. Few neutrophils 
(10/34) or plasma cells (2/34) were noted within the infiltrate in rare biopsies.
The cytological detail of these lymphomas was rather monomorphous and consisted 
predominantly of medium-sized lymphocytes (24/34). The tumor cells displayed oval or 
slightly indented nuclei with scant cytoplasm with indistinct cell boundaries (Figure 3f). A 
predominantly large cell infiltrate was identified in 3 biopsies.
Immunophenotypic and molecular data
All 34 skin biopsies analyzed with immunohistochemistry were CD3 positive and 34/34 
were CD8 positive while 7 biopsies had a CD4−/CD8− double negative phenotype and one 
of the CD8+ biopsies also showed weak CD4 co-expression. We noted CD8 expression to be 
of variable intensity from case to case (Figure 4a, Case 30). βF1 was positive in 27/33 
biopsies. The six βF1 negative biopsies were also negative for the γδ immunomarker. In 
addition, two biopsies expressed both, the γδ marker (γ3.20) and the αβ (βF1) T–cell 
receptor heterodimers (Figure 4c–f, Case 27). Four of the 30 biopsies tested had partial 
CD30 positivity, including the 2 biopsies with predominance of large cells. CD2 was 
negative in 56% (13/23) of the biopsies. CD56 was positive in 12% (4/34) of the biopsies 
and CD5 was positive in 33% (11/33) of the biopsies evaluated. CD45RA was expressed in 
61% (16/26) of the biopsies and CD7 was positive in 79% (23/31) of the biopsies. Co-
expression of CD7 and CD45RA was noted in 12/26 biopsies. Expression of at least one 
cytotoxic marker including T-cell intracellular antigen-1 (31/32) and granzyme-B (22/29) 
was noted in all biopsies with one exception (Figure 4b, Case 30). Epstein-Barr encoding 
region in situ hybridization was negative in all 31 biopsies evaluated. T-cell receptor 
clonality by polymerase chain reaction methods was detected in the skin of 57% (4/7) of the 
biopsies available for evaluation. T-cell clonality was also detected in the blood of two 
subjects. Only one case presented with the same clone in the skin and blood by T-cell 
receptor, which also had a small population by morphology (6%).
Clinical or Pathologic Parameters Associated with Survival Outcome (Table 4)
There was no statistically significant differences in the survival outcome between genders, 
race, length of disease (>6 months vs. <6 months), clinical ulcers, or constitutional 
symptoms at presentation, skin stage T1/ T2 versus T3, number of therapies used, high 
serum lactate dehydrogenase, or mucosal membrane involvement. A significant worse 
prognosis was noted in patients presenting with tumors at diagnosis. Extracutaneous 
involvement did not reach statistical significance, but there were only 4 patients with it and 
one of them was alive after allogeneic hematopoietic stem cell transplantation. No 
statistically significance difference in survival was found associated with large cell (small/
medium vs. large) or immunophenotypes CD2, CD5, CD7, CD45RA, CD45RA/CD7, 
CD4−/CD8−, CD30, granzyme B and CD56. None of the treatment modalities showed 
significant survival advantage (Table 2). Allogeneic hematopoietic stem cell transplantation 
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resulted in prolonged partial or complete remissions in 5 of 6 patients but did not reach 
statistical significance.
DISCUSSION
We have reviewed our experience with a rare and aggressive subtype of cutaneous T-cell 
lymphoma still considered a provisional entity by the latest World Health Organization 
classification of cutaneous lymphomas. CD8 positive aggressive epidermotropic T-cell 
lymphoma has been defined clinically by the abrupt presentation of extensive annular 
plaques with erosive features and ulceration (6, 7). This observation reflects the cytotoxic 
nature of the lymphoma cells which are embedded primarily in the intraepithelial 
compartments including epidermis and skin adnexa. The lymphoma cells contain cytotoxic 
granules, resulting in epidermal necrosis upon activation. The factors that trigger the 
cytotoxic events are poorly understood, but cases with marked epidermotropism of 
lymphoma cells without necrotic keratinocytes contrast with other cases with fewer 
lymphocytes yet with massive keratinocyte necrosis or ulceration. At least in some reported 
cases, phototherapy and interferon may have coincided with this activation of cytotoxic 
events (8). Angioinvasion and angiodestructive features have been occasionally reported in 
CD8 positive aggressive epidermotropic T-cell lymphoma (7, 9). While subtle involvement 
of dermal vasculature by the lymphoma cells was observed in a few cases, ulceration seems 
to be the direct result of epithelial necrosis from cytotoxic lymphocytes rather than a 
consequence of vaso-occlusion or angiodestruction as seen in natural killer-T cell 
lymphomas associated with Epstein-Barr virus infection. This pathomechanism of massive 
epidermal necrosis triggered by a clonal expansion of cytotoxic T-cells is also shared by 
pityriasis lichenoides acuta or Mucha-Habermann disease. Hence, it comes as no surprise 
that the febrile ulcero-necrotic variant of Mucha-Habermann can pose a diagnostic dilemma, 
as observed in 2 of our cases. By definition, extensive epidermotropism is a diagnostic 
requirement, but in some cases the epidermal lymphocytes remained localized in the lower 
epidermal layers. Furthermore, the burden of tumor cells may be dermal in thick plaque or 
tumor lesions with pagetoid extension into the surmounting epidermis.
As reported by Robson et al, despite extensive adnexotropism, clinical evidence of 
folliculotropism including follicular based papules (keratosis pilaris, lichen spinulosus, milia 
or cystic lesions) or alopecia mucinosa were not observed in our series (7). In addition, 
destruction of adnexal structures with resulting granulomatous reaction or mucinous 
degeneration as seen in folliculotropic mycosis fungoides do not seem to occur in primary 
cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma.
Unlike other cytotoxic lymphomas such as γδ T cell lymphomas that are often associated 
with immune dysregulation or natural killer-T cell lymphomas associated with epstein-barr 
virus infection, we have not identified any significant co-morbidities or predisposing factors 
associated with primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma 
(10). However, preceding skin signs of poorly defined papulo-squamous or eczematous 
dermatitis were observed in a several patients. The clinical impression of these preceding 
lesions varied from psoriasis to eczema or mycosis fungoides. We had the opportunity to 
review skin biopsies of preceding lesions of two cases which showed psoriasiform 
Guitart et al. Page 7
Mod Pathol. Author manuscript; available in PMC 2017 July 27.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
acanthosis with subtle scattered intraepidermal atypical lymphocytes in one case and 
folliculotropism and syringotropism with eosinophils in another case resembling 
adnexotropic mycosis fungoides. Previous reports of similar epidermotropic cytotoxic 
lymphomas initially misinterpreted as “ulcerative psoriasis” also emphasized the fact that a 
lymphoid-rich skin biopsy should be a warning sign not compatible with psoriasis vulgaris 
(11). In addition, we noted scattered necrotic keratinocytes in these early lesion biopsies, a 
finding rarely seen in psoriasis or mycosis fungoides.
As initially reported by the European group, the World Health Organization defines CD8 
positive aggressive epidermotropic T-cell lymphoma by the expression of CD8. However, we 
have observed cases with CD4/CD8 double negativity that otherwise fulfill clinical and 
pathological characteristics of this entity. Likewise, CD45RA, a marker commonly 
expressed in CD8 positive aggressive epidermotropic T-cell lymphoma, was negative or 
partially positive in many cases and hence not a reliable diagnostic marker. The variable 
CD45RA expression is not surprising since the marker is reversible with stronger expression 
in resting and naïve lymphocytes when antigenic stimulation is low (12). In addition, we 
observed variable expression of the T–cell receptor heterodimer markers. A small subset of 
cutaneous lymphomas with similar clinicopathological presentation expressing only γδ T–
cell receptor heterodimer with αβ negativity were reviewed and excluded for this study. 
However, a few other cases with αβ/γδ double positive or double negative expression were 
included. This unexpected variable expression of T–cell receptor heterodimers ranging from 
αβ/γδ T–cell receptor double positivity to double negativity has also been reported in 
natural killer-T-cell lymphomas (13). This observation may not be entirely surprising since 
the γδ immunomarkers for paraffin embedded tissue were not widely available when Berti 
et al published their initial case series (14).
A recent publication by Merrill et al highlighted aggressive primary cutaneous gamma delta 
T-cell lymphoma presenting with pagetoid epidermotropism.(15) We considered this 
diagnostic possibility for the two cases expressing the gamma T-cell receptor in addition to 
the beta T-cell receptor marker (cases 22 and 27). However, we felt the clinical and 
pathological findings of these cases was most consistent with the rest of the primary 
cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma cohort and as previously 
mentioned variable expression of alpha/beta and gamma/delta markers is occasionally 
observed in other cytototxic lymphomas. Based on our observation, we recommend the term 
primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma, to include not 
only the previously described CD8+/ T–cell receptor -β+ cases but the additional CD4/CD8 
double negative cases and/or cases with variable αβ/γδ heterodimer expression, as long as 
at least one T cell marker and one marker of cytotoxicity (i.e. T-cell intracellular antigen-1, 
perforin or granzyme-B) is expressed.
Our cohort confirms the poor prognosis of primary cutaneous aggressive epidermotropic 
cytotoxic T-cell lymphoma with rapid disease progression, poor response to chemotherapy 
and death often associated with complications of extensive epidermal necrosis and only 
rarely nodal or other extracutaneous involvement. In contrast to other cytotoxic lymphomas, 
hemophagocytic lymphohistiocytosis was not observed in any of our cases. We found one 
case report of primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma 
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complicated with hemophagocytic lymphohistiocytosis in the literature, but the diagnosis of 
this human immunodeficiency virus positive patient with epstein-barr virus expression in the 
intraepidermal lymphoid cells is questionable (16).
Besides the rare and equally aggressive epidermotropic variants of cutaneous γδ T-cell 
lymphomas, the differential diagnosis of primary cutaneous aggressive epidermotropic 
cytotoxic T-cell lymphoma includes CD8 positive mycosis fungoides, localized pagetoid 
reticulosis (Woringer-Kolopp disease) and type D lymphomatoid papulosis. These three 
indolent conditions can occasionally present with a similar complete or partial CD45RA+/
CD7+/CD8+ phenotype profile (7, 12). The histopathology of mycosis fungoides tends to be 
less pagetoid with more pleomorphic and convoluted nuclei and most importantly without 
necrotic keratinocytes. Intraepidermal aggregates of lymphocytes resembling Pautrier 
microabscesses were a common finding and hence may not help distinguish from mycosis 
fungoides. Localized pagetoid reticulosis (Woringer-Kolopp disease) and type D 
lymphomatoid papulosis can have similar biopsy findings including epidermal necrosis, but 
usually the clinical presentation does not pose a diagnostic dilemma. Nevertheless, one of 
our patients initially presented with a single lesion and the diagnosis of Woringer-Kolopp 
disease was considered, but extensive patches appeared shortly after.
Based on our experience, we feel that primary cutaneous aggressive epidermotropic 
cytotoxic T-cell lymphoma should be defined clinically by the rapid onset of erosive or 
ulcerated plaques with or without preceding skin lesions and should not be limited to 
immunophenotypic expression of CD8 or the αβ T–cell receptor heterodimer, but rather the 
identification of an atypical pagetoid T-cell infiltrate with cytotoxic granules and absence of 
CD4 expression. Molecular studies should demonstrate dominant T–cell receptor sequences. 
We also bring attention to the yet poorly defined preceding skin lesions reported in several 
of our patients and often misdiagnosed as psoriasis, eczema or mycosis fungoides. It remains 
an important goal to learn to recognize and diagnose these early stages. Tracking the 
evolution of T cell clones with high throughput sequencing may allow us to better 
understand these precursor lesions. While there is no evidence that early intervention will 
prevent the development of extensive ulceration with high morbidity, identification of these 
early stages may alert us to patients that should be closely followed avoiding 
immunosuppressive therapies, which could accelerate the course, as seen in some of our 
patients. Finally, our series highlights the failure of most standard cutaneous T-cell 
lymphoma therapies in treating this condition. In our experience, allogeneic hematopoietic 
stem cell transplantation appears to be the only therapeutic option associated with durable 
partial or complete remission raising the question of whether this treatment should be 
considered early on and prior to the development of extensive epidermal necrosis and 
ulceration which is often associated with a poor outcome. However the scarcity of reports of 
primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma still precludes us 
from establishing therapeutic guidelines.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Clinical presentation of PCAECyTCL in three different patients
a) Tumor presentation with exophytic hemorrhagic and necrotic nodules resembling 
pyogenic granuloma (Case 24). b) Extensive targetoid necrotic macules and plaques 
resembling severe pityriasis lichenoides acuta or erythema multiforme (Case 27). c) 
Ulcerated plaques involving genitalia (Case 23).
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Figure 2. Clinical presentation of PCAECyTCL in two different patients
a) Oral and nasal ulcerated macules (Case 25). b) Extensive annular erosive plaques some 
with hemorrhagic features (Case 25). c) Annular and arcuate ulcerated plaques and scars at 
sites of resolved lesions (Case 25). d) Annular erythematous plaques at presentation (Case 
26). e) Same patient as 2D now with extensive erosive confluent plaques a few months later 
(Case 26).
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Figure 3. Histopathological features of PCAECyTCL
a) H&E stains showing extensive full-thickness pagetoid exocytosis of medium sized 
lymphocytes without significant keratinocytes necrosis or dermal involvement (Case 25). b) 
Atrophic epidermis with pagetoid intraepidermal atypical small/medium lymphocytes 
mostly involving the lower levels of the epidermis. Occasional necrotic keratinocytes are 
noted (Case 34). c) Tumor lesion with a predominantly dermal infiltrate (Case 29). d) Same 
as C in higher magnification showing extensive pagetoid exocytosis in addition to a dense 
dermal infiltrate (Case 29). e) Marked lymphoid infiltration of eccrine coils on the left side 
and pilosebaceous unit on the right side (Case 26). f) High power of image e demonstrating 
atypical small lymphocytes in the eccrine coil (Case 26).
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Figure 4. Histopathological features of PCAECyTCL
Immunohistochemistries of case 30 illustrate in 3a with strong CD8 expression (a) and 
TIA-1 (b). Immunochemistries of case 27 illustrated in figure 1b including CD8 (c), 
granzyme B (d), and coexpression of γδ marker (e) and βF1 (f).
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Table 4
Clinical or pathologic parameters associated with survival outcome.
Parameter Cases (dead/total cases ) p-value
Gender Male 10/16 vs. female 3/8 .50
Race Caucasian 8/14 vs. others 1/6 .21
Length of disease before diagnosis 6m 9/12 vs. >6m 4/11 .09
Ulcers at presentation Present 7/15 vs. absent 6/9 .69
Constitutional symptoms Present 5/8 vs. absent 5/11 .36
Stage T1/T2 1/5 vs. T3 10/16 .11
Total number of therapies 1–3 therapies 8/11 vs. 4 – 13 therapies 4/12 .14
Abnormal LDH Abnormal 3/3 vs. normal 5/10 .16
Mucosal membrane involvement present 2/5 vs. absent 11/19 .51
Tumors at diagnosis Present 4/4 vs. absent 9/20 .04
Tumors at any time Present 10/15 vs. absent 3/9 .17
Extracutaneous disease Present 3/4 vs. absent 7/15 .31
Large cell (s/m vs Large) S/m 9/14 vs. large 4/10 .30
CD2 expression Positive 4/7 vs. negative 3/10 .14
CD5 expression Positive 4/10 vs. negative 8/13 .37
CD7 expression Positive 11/19 vs. negative 1/4 .69
CD45RA expression Positive 7/11 vs. negative 3/6 .77
CD45RA/CD7 expression Positive 6/10 vs. negative 7/13 .85
CD4-CD8- expression Positive 3/5 vs. negative 10/19 .42
CD30 expression Positive 1/3 vs. negative 11/20 .36
Granzyme B expression Positive 10/18 vs. negative 3/5 .95
CD56 expression Positive 2/2 vs. negative 11/22 .23
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